Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025European NeuropsychopharmacologyOpen Access

Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

NFNatalia E. Fares‐OteroMBMonika BuddeJLJonathan Laatsch

Discussion

Loading...

Member takes

Overview

Systematic review and meta-analysis reveal PGx-guided antidepressants enhance functional outcomes and quality of life in adults with anxiety and affective disorders.

Key Points

  • PGx-guided antidepressant treatment improved functional disability compared to treatment as usual.
  • The meta-analysis of three studies showed a mean difference of -2.85 in functional outcomes, indicating effectiveness.
  • Only six studies with a total of 2285 adult patients were included, limiting the analysis of heterogeneity and bias.
  • The findings suggest PGx-guided treatment may have modest benefits, but more research is needed due to the small number of trials.

Cite This Study

Fares‐Otero et al. (2025) studied this question.

synapsesocial.com/papers/68c23966b210217d6477bb2ehttps://doi.org/10.1016/j.euroneuro.2025.08.003
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative effectiveness of pharmacogenomic-guided versus unguided antidepressant treatment in major depressive disorder: new insights from subgroup and cumulative meta-analyses2025 · 9 citations
  2. 2Evidence level for pharmacogenetic testing in antidepressant treatment: a systematic review2025 · 3 citations
  3. 3Meta-analysis of Response and Remission Outcomes With a Weighted Multigene Pharmacogenomic Test for Adults With Depression2025
  4. 4177. A GENETICALLY INFORMED APPROACH TO ANTIDEPRESSANT PRESCRIPTION FOR YOUTH WITH MAJOR DEPRESSIVE DISORDER2025
  5. 5Psychotropic pharmacogenetics in adult populations: From basic science to clinical trials and health economics – An evidence-based overview for decision makers2025